The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 7 May 2025, approved teprotumumab (Tepezza). This is the first medicine to be licensed in the UK for adult patients with moderate to severe Thyroid Eye Disease (TED).
TED is an autoimmune condition where the immune system attacks the muscles and fat around the eyes. In TED, the immune system activates a protein called IGF-1R, causing inflammation and swelling in these tissues. Tepezza is designed to bind to IGF-1R to block its activation and signalling.
This medicine is administered via an intravenous drip directly into a vein by a healthcare professional.
Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said:
“Patient safety is our top priority. I am pleased to confirm the approval of teprotumumab, for the treatment of severe Thyroid Eye Disease.
“We’re assured that the appropriate regulatory standards of safety, quality and effectiveness for the approval of this new treatment have been met…
